Phase 2 Data for Progenics' 1404 Imaging Agent Presented at EANM Congress

By: via Benzinga
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that data from a Phase 2 trial of its PSMA imaging agent candidate, 1404, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.